Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

<p>Abstract</p> <p>Background</p> <p>Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces apoptosis in cancer cells.</p> <p>Results</p> <p>Ezatiostat was administered to 19 patie...

Full description

Bibliographic Details
Main Authors: Raza Azra, Galili Naomi, Mulford Deborah, Smith Scott E, Brown Gail L, Steensma David P, Lyons Roger M, Boccia Ralph, Sekeres Mikkael A, Garcia-Manero Guillermo, Mesa Ruben A
Format: Article
Language:English
Published: BMC 2012-04-01
Series:Journal of Hematology & Oncology
Subjects:
MDS
Ezatiostat
Lenalidomide
Phase 1
Non-deletion (5q)
Online Access:http://www.jhoonline.org/content/5/1/18

Internet

http://www.jhoonline.org/content/5/1/18

Similar Items